These findings suggest that incorporating PI3K δ/γ inhibitors during the production of CD8 + CAR-T cells can enhance their efficacy in eliminating CLL in vivo [77]. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.